Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion type Assertion NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_head.
- NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_provenance.
- NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion evidence source_evidence_literature NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_provenance.
- NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion SIO_000772 21396117 NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_provenance.
- NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion wasDerivedFrom befree-20150227 NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_provenance.
- NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion wasGeneratedBy ECO_0000203 NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_provenance.